Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Forma Therapeutics Holdings, Inc.
Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 05, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
July 29, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 12, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Announces Appointment of New Executive Team Members
June 30, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences
June 10, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics to Present at the Jefferies Healthcare Conference
June 03, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day
May 26, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 06, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
April 29, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022
February 23, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference
February 08, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee
January 13, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
January 07, 2022
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia
December 16, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease
December 11, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
November 30, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 12, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021
November 05, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting
November 04, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer
October 07, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics to Participate in Upcoming Investor Conferences
September 17, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 13, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021
August 06, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
June 14, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress
June 11, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
May 20, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics to Participate in Upcoming Investor Conferences
May 17, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021
May 06, 2021
From
Forma Therapeutics Holdings, Inc.
Via
Business Wire
Tickers
FMTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit